A Phase 1 interventional study of Clopidogrel and Aspirin in Cardiovascular Disease, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-02-23.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Basic science
Purpose of study is to evaluate a thrombosis chamber model
4,902 studies on the registry are indexed under Cardiovascular Diseases; 920 are open to participants now.
This study's enrollment of 15 is below the median of 100 across 2,738 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Clopidogrel · Drug: Aspirin
Tablets, Oral, 75 mg, Once daily, 8 days
Also known as: Plavix
Tablets, Oral, 325 mg, Once daily, 8 days
Evaluate ex vivo thrombosis chamber model by assessing the effect of anti-platelet agents on thrombus formation
Time frame: Period 2, Day 8
Assess variability of thrombosis chamber measurements
Time frame: Period 1 and Period 2
Assess relationship between platelet aggregation and thrombus formation
Time frame: Period 1 and Period 2
Safety and tolerability of multiple doses clopidogrel and aspirin
Time frame: From Day 1 through Study Discharge
This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb